Whole_genome_sequencing_of_lumefantrine_and_piperaquine_resistant_Plasmodium_berghei_ANKA-sc-2012-11-30T13:06:26Z-2448
Whole_genome_sequencing_of_lumefantrine_and_piperaquine_resistant_Plasmodium_berghei_ANKA
The following samples were provided as genomic DNA by Daniel Kiboi at The Kenya Medical Research Institute (KEMRI): The piperaquine sensitive parental clone 259cl1 and three resistant derivatives at different stages of the selection process (27th and 60th passage and after mosquito transmission). The lumefantrine sensitive parental clone 676m1cl1 and three resistant derivatives from different stages of the selection process (48th and 60th passage and after mosquito transmission). This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
To understand mechanisms of antimalarial drug resistance, separate P. berghei ANKA lines were selected in mice to become resistant to lumefantrine (LM) and piperaquine (PQ). Whole genome sequencing will be used to identify genomic changes that may be associated with drug resistance.